The Children's Tumor Foundation's Young Investigator Award program received a boost this month when the Boston Children's Hospital Neurofibromatosis Program decided to partner with CTF to help fund the 2017 Young Investigator Awards. Dr. David Miller of Boston Children's Hospital directs the research initiative focused on MPNST, a malignant neurofibroma occurring in a small minority of NF1 patients that typically has a poor treatment outcome.
Chronic illness in youth poses numerous challenges to the parents who care for them. Across various pediatric populations, psychological functioning in parents is compromised by the stress of having a child with special healthcare needs. This pilot study, Feasibility and Preliminary Efficacy of an Internet Support Group for Parents of a Child with Neurofibromatosis Type 1, investigated the feasibility and preliminary efficacy of an Internet Support Group (ISG) for parents of children with NF1.
Foundation President Annette Bakker Participates in Key Meetings Dedicated to Accelerating the Cure for Cancer
Last year, the Children's Tumor Foundation announced Synodos for NF1, a unique consortium bringing together a multidisciplinary team of scientists, clinicians, technicians, patients and other experts from world-class labs at academic and medical centers. These scientists have pledged to work together and share unpublished information, datasets, and results, thereby accelerating the drug development process.
The Children’s Tumor Foundation is pleased to announce that we will be co-sponsoring, in conjunction with the Center for Cancer Research and the Division of Cancer Epidemiology and Genetics of the National Cancer Institute (NCI) at the National Institutes of Health (NIH), a workshop that brings together international experts on the many aspects of malignant peripheral nerve sheath tumors (MPNSTs), which is a rare cancer that can develop in a small subset of patients with NF1.